BIVRX
Price
$17.17
Change
+$0.41 (+2.45%)
Updated
Dec 26 closing price
Net Assets
1.05B
NLSCX
Price
$18.77
Change
+$0.01 (+0.05%)
Updated
Dec 26 closing price
Net Assets
7.96B
Interact to see
Advertisement

BIVRX vs NLSCX

Header iconBIVRX vs NLSCX Comparison
Open Charts BIVRX vs NLSCXBanner chart's image
Invenomic Investor
Price$17.17
Change+$0.41 (+2.45%)
VolumeN/A
Net Assets1.05B
Neuberger Berman Long Short C
Price$18.77
Change+$0.01 (+0.05%)
VolumeN/A
Net Assets7.96B
BIVRX vs NLSCX Comparison Chart in %
View a ticker or compare two or three
VS
BIVRX vs. NLSCX commentary
Dec 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIVRX is a Buy and NLSCX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
NLSCX has more cash in the bank: 7.96B vs. BIVRX (1.05B). BIVRX pays higher dividends than NLSCX: BIVRX (3.58) vs NLSCX (0.00). BIVRX was incepted earlier than NLSCX: BIVRX (9 years) vs NLSCX (14 years). BIVRX (3.42) is less costly to investors than NLSCX (2.43). BIVRX is a more actively managed with annual turnover of: 170.00 vs. NLSCX (48.00). NLSCX has a lower initial minimum investment than BIVRX: NLSCX (1000) vs BIVRX (5000). NLSCX annual gain was more profitable for investors over the last year : 5.21 vs. BIVRX (3.31). BIVRX return over 5 years is better than : 55.00 vs. NLSCX (16.51).
BIVRXNLSCXBIVRX / NLSCX
Total Expense Ratio3.422.43141%
Annual Report Gross Expense Ratio3.422.43141%
Fund Existence9 years14 years-
Gain YTD1.2386.10520%
Front LoadN/AN/A-
Min. Initial Investment50001000500%
Min. Initial Investment IRAN/AN/A-
Net Assets1.05B7.96B13%
Annual Yield % from dividends3.580.00-
Returns for 1 year3.315.2163%
Returns for 3 years-7.5425.76-29%
Returns for 5 years55.0016.51333%
Returns for 10 yearsN/A45.61-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BFGBX43.280.01
+0.02%
BlackRock Capital Appreciation K
VPMCX180.67N/A
N/A
Vanguard PRIMECAP Inv
MXMVX14.66N/A
N/A
Empower Mid Cap Value Inv
GRGRX46.89-0.01
-0.02%
Goldman Sachs Equity Income R
RYOIX76.19-0.43
-0.56%
Rydex Biotechnology Inv